Data Sheet (Cat.No.T26986)

TargetMol

Cevoglitazar

Chemical Properties



CAS No. : 839673-52-8

Formula: C27H21F3N2O6S

Molecular Weight: 558.53

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Cevoglitazar (LBM-642) is a PPAR agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
Targets(IC50)	PPAR
In vivo	Cevoglitazar (0.5 mg/kg; 7 d) plasma levels of glucose and insulin were normalized.[1] Cevoglitazar (50 and 500 mg/kg; obese and insulin-resistant cynomolgus monkeys; 4 weeks) lowered food intake and body weight in a dose-dependent manner. In these animals, cevoglitazar also reduced fasting plasma insulin and, at the highest dose, reduced hemoglobin A1c levels by 0.4%.[1] Cevoglitazar (5 mg/kg) reduced BW gain and adiposity, independent of food intake. In the muscle, cevoglitazar improves the lipid profile via both PPARalpha- and PPARgamma-mediated mechanisms, and cevoglitazar reduced hepatic lipid concentration below baseline levels ($p < 0.05$). Metabolic profiling showed that in the liver, cevoglitazar functions largely through PPARalpha agonism resulting in increased beta-oxidation. Cevoglitazar only induced small changes to the lipid composition of visceral fat.[2]

Solubility Information

Solubility	DMSO: 50 mg/mL (89.52 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7904 mL	8.9521 mL	17.9041 mL
5 mM	0.3581 mL	1.7904 mL	3.5808 mL
10 mM	0.179 mL	0.8952 mL	1.7904 mL
50 mM	0.0358 mL	0.179 mL	0.3581 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Chen H, et al. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys. Endocrinology. 2010 Jul; 151(7):3115-24.

Laurent D, et al. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes Metab. 2009 Jun;11(6):632-6.